Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 04:44
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Harry and Meghan ring young online innovators after funding awards
Tough Times for VPNs? ExpressVPN Parent Company Lays Off 30% of Staff
Microsoft hires ousted OpenAI boss Sam Altman
Nvidia Hits Record High as AI Demand Fuels Blowout Forecast
University of Auckland Leverages Rimini ONE™ to Support, Manage, Protect and Extend the Life of its Oracle Application Investments
Lenovo ThinkReality VRX is Now Available in Select Markets Worldwide
Snowflake Announces Fifth Annual Data Drivers Awards Winners, Honoring Leaders Transforming The Future of Data, Apps, and Generative AI Across Industries
Families Paid More for College Last Year and Covered Half of Costs Out of Pocket, According to Sallie Mae’s ‘How America Pays for College 2023’